Zhou Zhe, Yuan Guanmin, Li Yang, Zhang Haocheng, Yu Shenglei, Shao Lingyun, Ai Jingwen, Zhang Wenhong
Department of Infectious Diseases, Shanghai Key Laboratory of Infectious Diseases and Biosafety Emergency Response, Shanghai Medical College, National Medical Center for Infectious Diseases, Huashan Hospital, Fudan University, Shanghai, China.
National Clinical Research Center for Aging and Medicine, Huashan Hospital, Fudan University, Shanghai, China.
Ann Hematol. 2025 Feb 20. doi: 10.1007/s00277-024-06174-0.
Patients with fever of unknown origin (FUO) can sometimes be accompanied by haemophagocytic lymphohistiocytosis (HLH), a life-threatening disease. The prognostic model and specific markers for the early prognosis and the optimized treatment regimen are of considerable research interest.
A total of 135 FUO/HLH patients were enrolled and classified according to the 60-day outcomes following diagnosis. 79 patients (including 5 patients lost in follow-up) enrolled from 2007 to 2015 served as the derivation cohort, and 56 patients from 2016 to 2023 served as the validation cohort. In the derivation cohort, 27 patients (27/74, 36.5%) survived within 60 days and multivariate analyses showed that age > 67 years (P = 0.003), baseline PLT < 42 × 10^9/L (P = 0.012) and LDH > 1505 U/L (P = 0.002) were associated with a higher mortality rate in HLH patients. The external validation proved the reliability of the prediction model. In derivation cohort, the median alteration of PLT (△PLT) were + 78 × 10^9/L and - 17 × 10^9/L in the survival and non-survival groups, respectively (P < 0.001). The median △LDH was - 197.5U/L in the survival group, while in the non-survival group was + 119U/L (P < 0.001).
Age, baseline LDH and PLT levels may predict early mortality in secondary HLH patients and identify patients in critical conditions. △LDH and △PLT levels were of high value to monitor the efficacy of therapeutic regimen and the disease progression in HLH patients.
不明原因发热(FUO)患者有时可伴有噬血细胞性淋巴组织细胞增生症(HLH),这是一种危及生命的疾病。早期预后的预测模型、特定标志物以及优化的治疗方案具有相当大的研究价值。
共纳入135例FUO/HLH患者,并根据诊断后的60天结局进行分类。2007年至2015年纳入的79例患者(包括5例失访患者)作为推导队列,2016年至2023年的56例患者作为验证队列。在推导队列中,27例患者(27/74,36.5%)在60天内存活,多因素分析显示年龄>67岁(P=0.003)、基线血小板计数<42×10^9/L(P=0.012)和乳酸脱氢酶(LDH)>1505 U/L(P=0.002)与HLH患者较高的死亡率相关。外部验证证明了该预测模型的可靠性。在推导队列中,存活组和非存活组血小板计数的中位数变化(△血小板计数)分别为+78×10^9/L和-17×10^9/L(P<0.001)。存活组LDH的中位数变化为-197.5 U/L,而非存活组为+119 U/L(P<0.001)。
年龄、基线LDH和血小板水平可能预测继发性HLH患者的早期死亡率,并识别病情危急的患者。△LDH和△血小板计数水平对于监测HLH患者治疗方案的疗效和疾病进展具有很高的价值。